Amwell's 2026 EBITDA Guidance Improved, but a 28% Visit Decline Still Limits the Bull Case

Amwell's 2026 outlook leaves little room for error

Amwell's latest guidance points to a business with better near-term losses but still limited proof of stabilization.

The company now expects adjusted EBITDA of ($9) million to ($7) million for 2026, after reporting a loss of $1.15 million in Q2. That is progress versus prior expectations, but it still leaves a narrow runway, especially with revenue guidance for Q3 at just $46 million to $48 million and total platform visits down 28.4% year over year.

Why the story has not broken completely

The main reason investors have not written the company off is financial flexibility. Amwell ended the quarter with $196 million in cash and marketable securities and zero debt. Management also said it still expects positive cash flows from operations projected for the fourth quarter this year. That does not prove demand has stabilized, but it does reduce the risk that another delay quickly becomes a funding problem.

Why the conference call matters

That is why the live conference call and webcast at 5 p.m. ET matters. Investors need to hear whether management can show a credible path to stabilizing usage and continuing to narrow losses, not just a cleaner-looking income statement.

Q2 improvements came from cost control and mix, not obvious demand recovery

The quarter improved on the income statement, but the clearest demand signal still looked weak.

What improved

Amwell posted total revenue of $52 million, a net loss of $9.6 million versus $10.3 million in the first quarter, and adjusted EBITDA of ($1.2) million. Those are genuine improvements.

What still looked soft

The underlying mix was less reassuring. Subscription revenue was $25.7 million, down approximately 36.5% year over year, even though it rose about 3.2% sequentially. AMG visit revenue, by contrast, was $24.4 million, up approximately 7.4% year over year, helped by revenue per visit of approximately $77, up about 6%. Total operating expenses also fell sharply, down approximately 38% year over year and down approximately 18% sequentially.

Taken together, the quarter looks more like a leaner business than a clearly healthier one. Better EBITDA can come from lower expenses and a higher share of visit revenue inside a shrinking top line. That is different from broad-based demand recovery.

The visit trend still matters most

The clearest warning signal remains volume. Total platform visits were down approximately 28.4% year over year, and that matters because Amwell still needs evidence that usage is stabilizing across the full platform, not just in one service line or niche.

If broader platform engagement keeps falling while subscription revenue remains under pressure, the EBITDA improvement may reflect a smaller, more efficient business rather than a durable turnaround. There is also a practical limit to how far expenses can come down without hurting product momentum, sales, or customer retention.

What will decide whether AMWL looks like a bargain or a trap

After the Adjusted EBITDA in the range between ($9) million to ($7) million outlook and total platform visits, down approximately 28.4% year over year, the key question is valuation framing. Investors are deciding whether Amwell can earn a higher-multiple software narrative over time, or whether it should keep trading like a distressed care-service business.

What would strengthen the bull case

Bulls do not need perfection. They need evidence that the business is becoming more recurring, more efficient, and less dependent on management asking the market to look beyond the current decline in platform volume.

What would weaken it

The bearish tell is not weak EBITDA by itself. It is another demand slide, continued subscription pressure, or Q3 results that miss the $46 million to $48 million revenue range without a clear explanation.

The outlook also becomes harder to defend if management can no longer support its expectation of positive cash flows from operations projected for the fourth quarter this year. Amwell's cash and marketable securities: $196 million at end of Q2 2026, with zero debt give it time, but not unlimited flexibility, to prove the model is stabilizing.